Mr. Pauly has more than 25 years of commercial launch experience in the biopharma industry. He has experience with disease-modifying agents in multiple therapeutic areas and across multiple commercial functions including sales, account management and market access. Mr. Pauly is currently Chief Commercial Officer at Alzheon with responsibility of building the commercial infrastructure and preparing for the launch of an oral disease-modifying therapy for the treatment of Alzheimer’s disease. Previously, Mr. Pauly has held commercial and executive roles at Johnson & Johnson, Genentech, AstraZeneca and Biogen where he supported launches and commercialization for multiple products including Remicade®, Rituxan®, Actemra®, Xolair®, Fasenra® and Aduhelm®.